In addition, clinical trials of tirzepatide, a dual GIP/GLP-1R agonist, have reported a weight loss of up to 20%, providing new hope that obesity and its related co-morbidities can be managed with medication rather than surgical interventions. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.